- Also known as
- Thymalfasin · Tα1 · Ta1 · Thymosin α1 · TA-1 · Zadaxin
- Class
- Thymic immunomodulatory peptide
- Form
- Lyophilised powder, 5 mg and 10 mg vials
- Sizes
- 5 mg · 10 mg
- Storage, dry
- −20 °C, dry and dark
- Storage, mixed
- 2–8 °C, use within 28 days of mixing (as generally reported for reconstituted peptides)
- BAC water per size
- 5 mg: 2 mL · 10 mg: 2 mL
What is Thymosin Alpha-1?
Thymosin Alpha-1 is a thymic immunomodulatory peptide. Research reported on it covers human. Several spellings in the literature point to the same material, among them Thymalfasin, Tα1 and Ta1. Its recorded sequence is 28 amino acids with an acetylated N-terminus, and the synthetic form is known as thymalfasin. Of the 5 studies set out below, all 5 are controlled human trials. The literature also refers to it as Thymalfasin, Tα1 and Ta1. Kept in Canadian stock as lyophilised powder in 5 mg and 10 mg vials, for laboratory research. It is not a drug and is not supplied for use in a person or an animal.
What the research shows
| Study | Model | Dose used | Duration | Finding |
|---|---|---|---|---|
| Wu J et al.2025 · BMJ · PMID 39814420 | Human, multicentre double-blind randomised placebo-controlled phase 3 trial, adults with sepsis (n=1106 randomised; 1089 analysed) | Not stated in the abstract (subcutaneous injection) | Every 12 hours for seven days | 28-day all-cause mortality was 23.4% with thymosin α1 and 24.1% with placebo (hazard ratio 0.99, P=0.93). No secondary or safety outcome differed significantly; subgroup analyses suggested a possible difference by age and diabetes status. |
| Wu X et al.2018 · Expert Opin Biol Ther · PMID 30063860 | Human, multicentre randomised open-label trial, HBV-related compensated cirrhosis (n=690) | Not stated in the abstract (added to entecavir) | 52 weeks, after 26 weeks of entecavir; median follow-up 38.2 months | Cumulative incidence of liver decompensation, liver cancer (HCC) or death was similar between groups. HCC incidence during combination treatment was 1.7% versus 2.1% with entecavir alone; both therapies were well tolerated. |
| Maio M et al.2010 · J Clin Oncol · PMID 20194853 | Human, randomised trial with five arms, metastatic melanoma (n=488) | 1.6, 3.2 or 6.4 mg, combined with dacarbazine with or without interferon alfa | Primary end point at 12 months; observed for up to 24 months | The 3.2 mg arms had 10 and 12 tumour responses versus four in the control group. Median overall survival was 9.4 versus 6.6 months (hazard ratio 0.80, P=.08), and adding Tα1 did not add toxicity. |
| You J et al.2006 · World J Gastroenterol · PMID 17075991 | Human, randomised controlled trial versus interferon alpha, with a historical control group, HBeAg-positive chronic hepatitis B (n=62; 30 historical controls) | 1.6 mg subcutaneously | Twice a week for six months, then six months of follow-up | Complete response at the end of follow-up was 48.3% (14 of 29) with Tα1 versus 27.3% with interferon alpha, a difference that was not statistically significant (P>0.05); against historical controls it was significantly higher. No side effects appeared in the Tα1 group. |
| Saruc M et al.2003 · J Pharm Sci · PMID 12820143 | Human, non-randomised comparative study, HBeAg-negative chronic hepatitis B (n=52; 27 in the Tα1 group) | 1.6 mg subcutaneously, twice a week, combined with interferon alpha-2b | 26 weeks of combination, then 26 weeks of interferon alone; follow-up to 18 months after treatment | Sustained response was 74% in the Tα1 plus interferon group versus 40% and 53.3% in the comparison groups (p = 0.13). At 18 months after treatment, 71.4% of the Tα1 group kept their response versus 10% and 20% (p = 0.0003). |
What these studies don't show: Trials exist, but their reach is narrower than it first looks. Participants are screened, many endpoints stand in as proxies, and most trials finish early. The results hold for the setting studied and no further. Testing establishes identity and purity; it is not evidence of an effect.
Every study links to its PubMed record. See all Thymosin Alpha-1 studies in the research library →
Thymosin Alpha-1 price in Canada: 5mg and 10mg vials
Buy Thymosin Alpha-1 in Canada in 2 vial sizes and a starter kit. Prices are in Canadian dollars, you pay by Interac e-Transfer or bank transfer, and orders are shipped from Canadian stock.
| Size | Price | Per mg |
|---|---|---|
| 5 mg | $41.00 | $8.20/mg |
| 10 mg | $52.00 | $5.20/mg |
Starter kit
Is Thymosin Alpha-1 available in Canada?
Thymosin Alpha-1 holds no Drug Identification Number, the mark Health Canada places on a drug it has authorized. That means Health Canada has never assessed it for safety, efficacy or quality. We stock it only as research material for the laboratory, not for any use in a person or an animal. How Health Canada treats research peptides →
Side effects reported in studies
Every statement is bound to the study that reported it. Any tolerability finding below is quoted from the study that recorded it. Human research on this scale cannot establish a safety profile.
Doses used in studies
Thymosin Alpha-1 FAQ
What is Thymosin Alpha-1?
Both suppliers and the literature list Thymosin Alpha-1 as a thymic immunomodulatory peptide. Research reported on it covers human. Borealis Peptides keeps it as lyophilised powder in 5 mg and 10 mg vials for in-vitro laboratory research. None of it is a medicine; it is not for human or veterinary use. The studies behind it appear on this page with the model each one used and what the authors reported.
Where can I buy Thymosin Alpha-1 in Canada?
Borealis Peptides dispatches Thymosin Alpha-1 from Canadian stock to research and business addresses within Canada, kept in 5 mg and 10 mg vials. HPLC testing covers every batch, and the certificate identifies the batch in your vial. Only laboratory-research orders are accepted.
Is Thymosin Alpha-1 legal in Canada?
Thymosin Alpha-1 holds no Drug Identification Number, the mark Health Canada places on a drug it has authorized. That means Health Canada has never assessed it for safety, efficacy or quality. We supply it solely as laboratory research material, with no use in a person or an animal intended. Because Health Canada has stated that "Research Use Only" labelling does not make a product legal to use in a person, we treat it as describing the intended supply and nothing more than that.
How much Thymosin Alpha-1 should I use?
Borealis Peptides provides no dosing, protocols or reconstitution volumes, and will not supply them on request. In laboratory work the quantity follows from the study design, something a supplier cannot sensibly fix. The figures on this page are what specific published studies used in their own models: a record of what was done, not a recommendation.
What human evidence is there for Thymosin Alpha-1?
Among the 5 cited studies, all 5 are controlled human trials and the remainder are animal or cell work. Every row states its model, the quantity used and what the authors reported, letting each study be weighed directly rather than via a summary.
How long does Thymosin Alpha-1 keep?
While sealed, hold it at −20 °C in the dark. In solution it is kept at 2–8 °C. As a dry powder it travels at room temperature and goes cold on arrival. Keeping it dark and at a steady temperature counts for more than how quickly it arrived.
How is the purity of Thymosin Alpha-1 confirmed?
Identity and purity are verified by HPLC for each batch, not once for the whole product. The certificate names the batch it covers, and that batch number is printed on the vial, so a result can be traced back to the exact material behind it. Quote your order number and we will send it.
How does Thymosin Alpha-1 compare with TB-500 and Epitalon?
These are distinct compounds with distinct published records, and this site does not rank them. TB-500 and Epitalon carry 7 cited studies and 8 cited studies on their page against 5 here. The useful comparison lies between the two study tables and the models behind them.
Why is Thymosin Alpha-1 named in a Health Canada advisory?
Because it was among the peptides seized from sellers offering unauthorized injectable products online. The advisory deals with material sold for people to inject without authorization. Everything Borealis Peptides ships is research material for in-vitro work; nothing is sold for injection or for any use in a person, the distinction the advisory rests on.







